Lee Placito Professor of Gastroenterology
Jack Satsangi is the Lee Placito Professor of Gastroenterology, University of Oxford; a Governing Body Fellow at Green Templeton College; and an Honorary Consultant Physician in Oxford University Hospital NHS Trust. He qualified in Medicine from St Thomas’s Hospital Medical School, London in 1987; and he completed his postgraduate training in clinical and academic medicine in Oxford as an MRC Fellow and Clinician Scientist, working with Derek Jewell and John Bell. He completed his DPhil in 1996 on the genetics of inflammatory bowel disease.
In 2000, Jack succeeded the late Anne Ferguson as Professor of Gastroenterology in Edinburgh, with the intention of building on her legacy to develop a centre of excellence in inflammatory bowel disease. He returned to Oxford to take up his present post in 2018. He continues to hold an honorary chair in the University of Edinburgh.
Jack has combined care of patients with Crohn’s disease and ulcerative colitis with basic, clinical and translational research; and post-graduate and undergraduate teaching. His areas of clinical interest have centred on complex and challenging IBD – and have included the management of severe colitis; the management of childhood-onset disease; the safety and efficacy of biological agents, and of novel therapeutic approaches; and the introduction of personalised medicine into clinical practice.
He has been involved in a number of important research advances and publications, including the discovery of cytokine dysregulation in IBD; the definition of the genetic architecture of inflammatory bowel disease; the re-classification by phenotype of inflammatory bowel disease; investigation of gene-environmental interactions; disease epigenetics, and multi-omic analyses in biomarker discovery. He currently is Chief Investigator of the global ICARUS – IBD consortium assessing Covid-19 impact in IBD, led from Oxford and New York; and he leads a number of other initiatives in personalising care, and treatment options.
His current research interests are translational. Laboratory studies are centred on the personalisation of care in inflammatory bowel disease, with a focus on the application of multi-omic technologies in the definition of phenotype, disease progression and drug response. Epigenomic analysis in both children and adults is a key area of interest. Clinical studies focus on the de-escalation of biological therapy; the response to Covid19 and vaccination in patients with inflammatory bowel disease; the development of predictive indices in severe colitis; and the development of non-immunogenic anti-TNF therapy.
Jack has been Secretary of the BSG IBD Committee, and was the first Chair of the BSG IBD Research Committee. He has led National and Regional NIHR Speciality Groups in Gastroenterology; as well as a co-ordinating a series of international research consortia supported by the European Community, and Helmsley Trust. He represents the Royal College of Physicians on the Board of the UK IBD Registry. He has supervised a series of research-active clinicians and students in UK and Europe. He is a Fellow of the Academy of Medical Sciences and of the Royal Society of Edinburgh.
Jack has been a Medical Advisor to the Crohn’s Colitis UK Charity for over 20 years; and has acted as a Trustee or Committee member to CICRA and CORE/GUTS-UK. He has led a series of recent initiatives in increasing Patient and Public understanding of research, in respect to Covid-19 as well as new therapeutic options.
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research
Alexander JL. et al, (2023), Gut
The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.
Sun Y. et al, (2023), Am J Gastroenterol
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Shubhakar A. et al, (2023), Journal of Crohn's and Colitis
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
Chen J. et al, (2023), Aliment Pharmacol Ther
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E. et al, (2023), Lancet Gastroenterol Hepatol